Healthequity is a leading provider of health savings accounts and other consumer-directed benefits, facilitating individuals and employers in managing healthcare expenses. The company offers a robust platform that integrates various services, including healthcare spending accounts, wellness services, and insurance products, aimed at empowering consumers to make informed healthcare decisions. By promoting cost-saving strategies and enhancing access to critical healthcare resources, Healthequity plays a vital role in the healthcare ecosystem, making it easier for users to navigate their financial responsibilities associated with medical care. Read More
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Based on fundamental and technical analysis of NASDAQ:HQY we ask: Why HEALTHEQUITY INC (NASDAQ:HQY) Is a Standout High-Growth Stock in a Consolidation Phase.
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of HealthEquity, Inc. (NASDAQ: HQY) resulting from allegations that HealthEquity may have issued materially misleading business information to the investing public.
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HealthEquity, Inc (“HealthEquity” or the “Company”) (NASDAQ: HQY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.
